CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The equity awards require continued employee service through each vesting date over four years.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
On November 5, 2026, as an inducement material to acceptance of employment with CareDx, 21 new employees were awarded restricted stock units (RSUs) for an aggregate of 33,375 shares of common stock.
The RSUs will vest over four years, with
The RSU awards were made pursuant to the Company’s 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About CareDx
CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit www.caredx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261106719831/en/
CareDx
Media Contacts
Natasha Moshirian Wagner
nwagner@caredx.com
Investor Relations
Nina Deka
investor@caredx.com
Source: CareDx, Inc.